Syndromic Panel-Based Testing in Clinical Microbiology.
The recent development of commercial panel-based molecular diagnostics for the rapid detection of pathogens in positive blood culture bottles, respiratory specimens, stool, and cerebrospinal fluid has resulted in a paradigm shift in clinical microbiology and clinical practice. This review focuses on U.S. Food and Drug Administration (FDA)-approved/cleared multiplex molecular panels with more than five targets designed to assist in the diagnosis of bloodstream, respiratory tract, gastrointestinal, or central nervous system infections. While these panel-based assays have the clear advantages of a rapid turnaround time and the detection of a large number of microorganisms and promise to improve health care, they present certain challenges, including cost and the definition of ideal test utilization strategies (i.e., optimal ordering) and test interpretation.
['Ramanan|Poornima|P|', 'Bryson|Alexandra L|AL|', 'Binnicker|Matthew J|MJ|', 'Pritt|Bobbi S|BS|', 'Patel|Robin|R|']
D006801:Humans D007239:Infections D025202:Molecular Diagnostic Techniques D014481:United States D014486:United States Food and Drug Administration
molecular methods multiplex PCR syndromic testing